These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37188274)

  • 1. Enhanced sensitivity of neutralizing antibody detection for different AAV serotypes using HeLa cells with overexpressed AAVR.
    Zheng Z; Ye J; Leng M; Gan C; Tang N; Li W; Valencia CA; Dong B; Chow HY
    Front Pharmacol; 2023; 14():1188290. PubMed ID: 37188274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adeno-associated Virus (AAV) Serotypes Have Distinctive Interactions with Domains of the Cellular AAV Receptor.
    Pillay S; Zou W; Cheng F; Puschnik AS; Meyer NL; Ganaie SS; Deng X; Wosen JE; Davulcu O; Yan Z; Engelhardt JF; Brown KE; Chapman MS; Qiu J; Carette JE
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28679762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor.
    Dudek AM; Pillay S; Puschnik AS; Nagamine CM; Cheng F; Qiu J; Carette JE; Vandenberghe LH
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Species Permissivity: Structure of a Goat Adeno-Associated Virus and Its Complex with the Human Receptor AAVR.
    Large EE; Silveria MA; Weerakoon O; White TA; Chapman MS
    J Virol; 2022 Dec; 96(24):e0148422. PubMed ID: 36453885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive biophysical characterization of AAV-AAVR interaction uncovers serotype- and pH-dependent interaction.
    Fu Y; Choudhary D; Liu N; Moon Y; Abdubek P; Sweezy L; Rosconi M; Palackal N; Pyles E
    J Pharm Biomed Anal; 2023 Sep; 234():115562. PubMed ID: 37441888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering a highly durable adeno-associated virus receptor for analytical applications.
    Yoshida K; Tsunekawa Y; Kurihara K; Watanabe K; Makino-Manabe Y; Wada M; Tanaka T; Ide T; Okada T
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101157. PubMed ID: 38152699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATF6-Mediated Unfolded Protein Response Facilitates Adeno-associated Virus 2 (AAV2) Transduction by Releasing the Suppression of the AAV Receptor on Endoplasmic Reticulum Stress.
    Cui M; Zhao Q; Wang J; Si Y; Cheng S; Ding W
    J Virol; 2022 Feb; 96(3):e0110321. PubMed ID: 34851146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
    Sierra-Delgado JA; Likhite S; Bautista PK; Gómez-Ochoa SA; Echeverría LE; Guío E; Vargas C; Serrano NC; Meyer KC; Rincon MY
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryo-EM structure of adeno-associated virus 4 at 2.2 Å resolution.
    Zane G; Silveria M; Meyer N; White T; Duan R; Zou X; Chapman M
    Acta Crystallogr D Struct Biol; 2023 Feb; 79(Pt 2):140-153. PubMed ID: 36762860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An essential receptor for adeno-associated virus infection.
    Pillay S; Meyer NL; Puschnik AS; Davulcu O; Diep J; Ishikawa Y; Jae LT; Wosen JE; Nagamine CM; Chapman MS; Carette JE
    Nature; 2016 Feb; 530(7588):108-12. PubMed ID: 26814968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Structure of an AAV5-AAVR Complex at 2.5 Å Resolution: Implications for Cellular Entry and Immune Neutralization of AAV Gene Therapy Vectors.
    Silveria MA; Large EE; Zane GM; White TA; Chapman MS
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33218165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced transduction of mouse salivary glands with AAV5-based vectors.
    Katano H; Kok MR; Cotrim AP; Yamano S; Schmidt M; Afione S; Baum BJ; Chiorini JA
    Gene Ther; 2006 Apr; 13(7):594-601. PubMed ID: 16341060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent engagements between adeno-associated viruses with their cellular receptor AAVR.
    Zhang R; Xu G; Cao L; Sun Z; He Y; Cui M; Sun Y; Li S; Li H; Qin L; Hu M; Yuan Z; Rao Z; Ding W; Rao Z; Lou Z
    Nat Commun; 2019 Aug; 10(1):3760. PubMed ID: 31434885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies.
    Chhabra A; Bashirians G; Petropoulos CJ; Wrin T; Paliwal Y; Henstock PV; Somanathan S; da Fonseca Pereira C; Winburn I; Rasko JEJ
    Mol Ther Methods Clin Dev; 2024 Sep; 32(3):101273. PubMed ID: 39022744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants.
    Emmanuel SN; Smith JK; Hsi J; Tseng YS; Kaplan M; Mietzsch M; Chipman P; Asokan A; McKenna R; Agbandje-McKenna M
    J Virol; 2022 Feb; 96(3):e0125121. PubMed ID: 34757842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.